Stock Comparison

KALA vs UNH

KALA BIO Inc vs UnitedHealth Group Inc

The Verdict

KALA takes this one.

Winner

KALA

KALA BIO Inc

2.5

out of 10

Risk Trap

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

N/A

Market Cap

$276.2B

N/A

P/E Ratio

22.9

N/A

Profit Margin

2.7%

N/A

Return on Equity

12.5%

N/A

Debt-to-Equity

0.0

Aggressive

Overall Risk

Moderate-High

2.5

DVR Score

0.3

The Deep Dive

KALA2.5/10

KALA BIO Inc. remains a highly speculative, pre-revenue biotech with 10x growth potential contingent on successful clinical trials for XP-898 in rare ocular diseases. The significant 37.5% decline in market capitalization to $0.20B in just 22 days since the last analysis reflects a material deterioration in market confidence regarding its financial outlook or development timeline. While the unmet ...

Full KALA Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.